Healthcare / BiotechnologyShanghai
$34.75
+0.51 (+1.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-105.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
173.8x
↑EV/EBITDA
31.0x
↑ROE
1.3%
↑Gross Margin
42.5%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-58.2%
FCF CAGR
—
FCF margin
-23.3%
FCF / Net income
-1.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $451.3M · net income $69.4M · FCF $-105.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $451.3M | $451.3M | $540.7M | $503.4M | $6.17B |
| Net Income | $69.4M | $69.4M | $192.3M | $141.6M | $3.04B |
| EBITDA | $123.5M | $123.5M | $264.2M | $208.9M | $3.57B |
| EPS | 0.55 | 0.55 | 1.51 | 1.11 | 23.95 |
| Gross Margin | 42.5% | 42.5% | 39.1% | 42.3% | 74.8% |
| Operating Margin | -3.4% | -3.4% | 1.5% | 5.5% | 60.0% |
| Net Margin | 15.4% | 15.4% | 35.6% | 28.1% | 49.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 8.87 | 8.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-105.0M | $-105.0M | $-32.0M | $-959.9M | $3.12B |
| Returns | |||||
| ROE | 1.3% | 1.3% | 3.7% | 2.8% | 56.2% |
| Valuation | |||||
| P/E | 173.75 | 173.75 | 23.32 | 35.61 | 2.58 |
| EV/EBITDA | 30.96 | 30.96 | 15.24 | 22.59 | 1.62 |
| P/B | 0.85 | 0.85 | 0.86 | 0.99 | 1.45 |
| Growth & Yield | |||||
| Revenue Growth | -16.5% | -16.5% | 7.4% | -91.8% | — |
| EPS Growth | -63.6% | -63.6% | 36.0% | -95.4% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
77.6%
EPS terminal req.
$3.08
Spread vs growth
-141.2%
5Y implied EPS CAGR
46.7%
EPS terminal req.
$3.73
Spread vs growth
-110.2%
10Y implied EPS CAGR
27.0%
EPS terminal req.
$6.01
Spread vs growth
-90.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.4%
Start / end P/E
24.2x → 63.2x
EPS bridge
1.51 → 0.55
Residual
-102.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.